In chronic paroxysmal hemicrania (CPH), some patients have now been treated with indomethacin for upwards of 10 years, with no signs of development of insensitivity to the drug. On the contrary, it seems to be possible to reduce the dosage over time in some patients.
Many patients with the "Jabs & jolts" syndrome (6) are also to a considerable extent responsive to indomethacin. Tachyphylaxis does not seem to develop in this syndrome either. Jabs & jolts may be similar to "Ice-pick pain" (7) and "Needle in the eye" (8). It is found not only in migraine as considered by Raskin & Schwartz (7), but is an integral part of other headaches as well. In addition, it seems to exist as a solitary phenomenon, in other words without any clear link to other established headache entities.
Cluster headache patients generally benefit from modern therapy, be it from attack therapy, i.e. oxygen or ergotamine, or from protracted courses of drugs, i.e. ergotamine, lithium, pizotifen, methysergide, and prednisone (9, 10), or combinations thereof. A major advantage in the episodic form of cluster headache is, of course, the fact that the therapeutic agent only has to be administered continuously during the cluster period itself, i.e. during a limited time span.
In the chronic form of cluster headache the situation is entirely different, since a continuous usage of the therapeutic agent is necessary (11) . The patient will accordingly be exposed to all the potentially untoward effects of drugs such as prednisone, lithium, and methysergide. From a therapeutic point of view, it is possible that the chronic variety may in itself be a more serious form of cluster headache, less responsive to pharmaceutical intervention than the cyclic form.
Some cervicogenic headache (2) cases seem to respond partly to NSAIDs, but otherwise there are no established treatments for cervicogenic headache.
In migraine, a chronification of the headache takes place with time, a continuous headache being superimposed upon the attacks. The chronification may conceivably be caused by factors such as abnormal personality profile, stress, hypertension, or cigarette smoking (12, 13) , but may also be caused by the very drugs themselves, be it ergotamine (14, 15) or analgesics (16) . Seemingly, protracted use of these drugs, or even overuse over a more limited time span, may be harmful.
New drugs about to appear on the market as antimigraine agents are the Ca-entry blocking agents (17, 18) and the serotonin M receptor blocking agents (19) . These may change the therapeutic prospect to some extent, but the therapy of migraine will nevertheless still leave much to be desired.
It is remarkable that some of the best therapeutic agents that we have in the headache field are linked to the prostaglandin system: In CPH, the indomethacin effect seems to be absolute as far as we know at present (6) . Prednisone has an effect in 70-80% or more of cluster headache cases (20). Therapeutic "failures" seem at least partly to be related to the tapering of the dosage, attacks usually re-appearing at 10-20 mg per day (21). Conversely, prednisone has only a moderate effect in CPH and indomethacin seems not to have any clear effect in regular cases of cluster headache (22, 23) .
Some NSAIDs have also been tested in migraine: Tolfenamic acid (24) seems to have an attack-relieving efficacy in line with ergotamine. Recently, after the introduction of high naproxen doses in migraine therapy, favourable results have been observed in prophylaxis as well as in the therapy of the acute attack (25, 26, 27) . Indomethacin, on the other hand, has not proved particularly potent in counteracting migraine attacks (28) .
The latter development tends to show that even the migraine process may be favourably influenced by some NSAIDs. However, the extent of the influence is clearly less than the influence of indomethacin in CPH and prednisone in cluster headache.
There are headaches influenced markedly by piroxicam and not by indomethacin and naproxen (Sjaastad: unpublished observations), but these seem to be so inhomogeneous that we have not dared try to classify them so far. Some of the cases with the most notable effect, however, may seem to fall within the "cervicogenic headache" category (2) .
All the available artificial antiphlogistics were tried in the few cases of CPH we had at the time (22) , i.e. indomethacin, butazolidine, oxyphenbutazon, and ketoprofen (Rhone Poulenc), and later tolfenamic acid, naproxen, ibuprofen, and piroxicam (Sjaastad: unpublished observations). The discrepancy between indomethacin on the one hand and all the other tested ones on the other was drastic. If only one of the NSAIDs had been tested in CPH as a "typical" representative of the group, this therapeutic opportunity might have been lost. This experience leads us to the belief that it is of the utmost importance that all available NSAIDs are tested even in migraine.
It is possible that several of the "non-structural" headaches have a common denominator or a common "step" in the pathogenesis of attack.
All old-and new-NSAIDs should therefore be tested systematically in migraine and migraine-like headaches. Even small changes in the molecule may be enough to change the therapeutic potential of the drug. This may depend on the relative potency of these drugs to inhibit the cyclo-oxygenase and the phospholipase, or on tissue distribution of the various drugs. The pharmaceutical industry should therefore be encouraged to make new NSAIDs for use in migraine.
